Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.

Journal of clinical pharmacology - 1 Jan 2019

Vourvahis Manoli, McFadyen Lynn, Nepal Sunil, Valluri Srinivas Rao, Fang Annie, Fate Gwendolyn D, Wood Linda S, Marshall Jean-Claude, Chan Phylinda L S, Nedderman Angus, Haynes Julian, Savage Mark E, Clark Andrew, Smith Kimberly Y, Heera Jayvant

Abstract excerpt

Maraviroc is a C-C chemokine receptor type-5 antagonist approved for the treatment of HIV-1. Previous studies show that cytochrome P450 3A5 (CYP3A5) plays a role in maraviroc metabolism. CYP3A5 is subject to a genetic polymorphism. The presence of 2 functional alleles (CYP3A5*1/*1) confers the extensive metabolism phenotype, which is rare in whites but common in blacks. The effect of CYP3A5 genotype on maraviroc...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Healthy Volunteers

Share to HIV Fusion Inhibitors

Share to HIV Infections

Share to Treatment Outcome

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 30192390
DOI: 10.1002/jcph.1306
PMCID: PMC6586010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.PMID 30192390Read ↗

CYP3A5 Genotype Impacts Maraviroc Concentrations in Healthy VolunteersSemantic proximity Read ↗

Maraviroc: a review of its use in HIV infection and beyond.Semantic proximity Read ↗

Pharmacogenomics of Antiretroviral Drug Metabolism and TransportSemantic proximity Read ↗

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.Semantic proximity Read ↗

Pharmacogenomics of CYP3A: considerations for HIV treatment.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapySemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapySemantic proximity Read ↗

Human genetic variability and HIV treatment response.Semantic proximity Read ↗

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens.Semantic proximity Read ↗

A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.Semantic proximity Read ↗

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.